International Conference on

Chronic Obstructive Pulmonary Diseases

Theme: Modern Evolutions in the field of Pulmonology

Event Date & Time

Event Location

Paris, France

18 years of lifescience communication

Performers / Professionals From Around The Globe

Tracks & Key Topics

COPD 2019

About us

Euroscicon is proud to host a conference on COPD (Chronic Obstructive Pulmonary Diseases) taking place on October 30-31 in Paris, France. The conference is themed around “Modern Evolutions in the field of Pulmonology” with the aim to bring together a wide audience of industry, healthcare, research, and medical practitioners, pulmonologist to educate and bring about a fruitful debate on the confined topics. 

The COPD 2019 will be a great event to network, learn and engage with professionals in the field of Pulmonology, respiratory diseases, lungs.  

The Organizing Committee has done its best to set up a framework that we think will allow for a creative interplay of ideas. All we need now is to convert the extensive program on paper to an active and a vibrant forum in person through your active participation.


Who should attend?

  • Pulmonologist
  • Medical Colleges
  • Pulmonology Associations and Societies
  • Research Labs
  • Manufacturing Medical Devices Companies
  • Doctors and Surgeons in COPD and Lung disorder
  • Academic professionals
  • Research Scientists and their members
  • Business Entrepreneur
  • Medical equipment manufacturers
  • University and training institutions

Why to attend?

COPD 2019 provides a golden opportunity to meet with the leading national and international speakers who will discuss the latest advancements in COPD and to the related diseases worldwide. Conference unites individuals or eminent personalities from all over the world, who share a common discipline or field. This conference is a collaborative event for the researchers from both business and academic background and offers current and recent information on the management of Asthma, lung cancer, as well as the possible therapies and strategies to shape the future of lung and COPD research. We encourage physicians, nurses, researchers and scientists as well as patients and advocates in the pulmonology field and those interested in attending this 2-days Conference.


Top Associations and Societies of COPD:




Track 1:  Asthma and COPD:

Asthma is a typical fiery infection in aviation routes of the lungs. Asthma influences within dividers of aviation routes are swollen or flared and cause unfavourably susceptible asthma. Swelling makes the aviation routes significantly smaller. Cells in the aviation routes will in general reason more bodily fluid generation. Discharge is a thick, sticky fluid that can facilitate slim aviation routes. This chain response can result in respiratory infection side effects and may cause unfavourably susceptible maladies. It is mostly described by reversible wind stream obstacle and bronchospasm. Asthma is characterized by the recurrence of side effects, constrained expiratory volume in one moment, and pinnacle expiratory stream rate. These measures may happen a couple of times each day or a couple of times each week. Contingent upon the individual, they may turn out to be more awful around evening time or with exercise. Asthma can't be restored however with better treatment, individuals can control and dynamic their lives.

Track 2: Epidemiology Of COPD

Chronic obstructive pulmonary disease (COPD) is accountable for early impermanence, high death rates and significant rate to health systems. Active smoking remains the main risk factor, but other issues are becoming better known, such as occupational factors, infections and the role of air pollution. The occurrence of COPD differs according to country, age, and sex. This disease is also associated with significant comorbidities. COPD is a complaint that contains various phenotypes, the continuum of which remains under debate. The major challenge in the coming years will be to prevent the onset of smoking along with early recognition of the disease in the general population. This may represent weakening in the patient's premorbid condition such that hypoxemia worsens, and hypercapnia progresses during a comparatively inconsequential respiratory tract infection, which may be viral or bacterial


Track 3: Idiopathic pulmonary fibrosis:

Idiopathic pulmonary fibrosis (IPF) is a type of lung disease that consequences in scarring (fibrosis) of the lungs for an unidentified reason. Over time, the scarring gets worse and it becomes hard to take in an unfathomable breath and the lungs cannot take in enough oxygen. IPF is a form of interstitial lung disease, primarily relating the interstitial (the tissue and space around the air sacs of the lungs), and not right affecting the airways or blood vessels. There are many other types of interstitial lung disease that can also reason inflammation and/or fibrosis, and these are treated inversely.


Track 4: Immune Responses in COPD:

In chronic pulmonary disease immune dysfunction happens. Chronic irritation contributes to lung damage, involves of innate and adaptive immune responses. wide-ranging immune dysfunction due to the occurrence and functional action of T regulatory cells, CD4+ exhausted effector T cells and myeloid-derived suppressor cells. Manipulation of these immunosuppressive systems in COPD could deliver a rational strategy to restore functional immune responses, decrease exacerbations, and progress lung function. It facilitates the occurrences of respiratory tract infections additional proceeds to the pathological appearances of the disease. Inflammation is conveyed by the initiation of defective immune responses that support to worsening the inflammatory lung and disease brutality. Advanced approaches to adaptive immune responses could be beneficial in avoiding the adverse consequences of most of the inflammatory responses in the lungs.


Track 5: Advanced Respiratory Disease Treatment

Currently, patients with Respiratory diseases use numerous devices, which help the subtraction of mucus from the Airways and the development of pulmonary function. Monotonous respiratory organ accomplishes, and metabolism muscle testing is recommended in youngsters with Neuromuscular Disease, however, these trials are maintained non-invasive voluntary manoeuvres, like the measuring of respiratory organ volumes and supreme static pressures, which young youngsters might not forever be able to achieve. Fundamentally, before the treatment Observation metabolism muscles in youngsters with NMD might advance understanding of the explanation of NMD and therefore the analysis of sickness severity. Now devices seem to increase patients' compliance with regular treatment, because they present many assistances, as an independent application, full control of therapy and easy use.

Track 6: Lung Carcinoma

Lung cancer is the foremost reason of cancer-related death worldwide. About 85% of cases are correlated to cigarette smoke and is a malignant tumor characterized by uncontrolled cell growth in tissues of lungs and infrequently to other parts of the body. The cases are frequently caused by a combination of genetic factors and exposure to radon gas, second-hand smoke, asbestos or other forms of air pollution. Lung cancer may be perceived on computed tomography and chest radiographs. Lung cancers are of two types, they cultivate and spread differently are small cell lung cancer and non-small cell lung cancers. The lungs are giant, the tumor grows in them for a continued time before they are found. Small-cell lung cancer signifies about 15 to 20 %of lung cancers whereas Non-Small cell lung cancer represents about 80%. More than two-thirds of non-smokers having lung cancer are women, and maximum of them possess adenocarcinoma. The universal diagnosis of lung cancer is poor because doctors tend not to find the disease until it is at a progressive phase. The persistence rate in five years is around 54% for early phase lung cancer that is restricted to the lungs, but only around 4% in advanced, inoperable lung cancer.


Radiation therapy

Pulmonary lobectomy


Chronic respiratory infections


Track 7: Pediatric Pulmonology

Chronic pulmonary disorder is a chief risk issue of children’s death. The sequence of studies on pediatric pulmonary disorder specifies overlapping age clusters from birth to late middle age that early life event which includes prenatal influences on lung growth and agendas the child at increased risk for future COPD. Several signs are phlegm production, chronic cough, frequent lung infections, and trouble doing daily activities because of breathlessness. Pediatric pulmonology is based on diagnosis, treatment, and accomplish children from birth to 21 years old with breathing and lung diseases. The COPD disorders in infants comparable pneumonia, asthmatuberculosis, complicated chest infections are cured pediatric pulmonologists.


Track 8: Pathophysiology of COPD

Fundamentally, the pathophysiology of COPD is quickly unveiling. There will be some physiological modification which ultimately impacts the quality of life and survival in the natural progress of COPD when the pathological significances of the COPD inflammation induce a sequence of physiological changes. Fibrotic remodeling of the airways results in fixed airway narrowing initiating increased airway resistance which does not completely revert even with bronchodilators. Emphysema also decreases lung elastic recoil pressure which leads to a reduced driving pressure for expiratory flow through narrowed and poorly supported airways in which airflow resistance is significantly increased.

Antitrypsin Deficiency

Bronchial Hyperreactivity



Track 9: Pulmonary Hypertension

Pulmonary hypertension is a kind of high blood pressure that disturbs the arteries in the lungs and the right side of the heart. These are the serious environments that become progressively worse and are occasionally fatal. These fluctuations can reason the walls of the arteries to become thick and stiff, and extra tissue may form. The blood vessels can also become inflamed and tight. The symptoms are categorized by chest pain, swelling in ankles, legs.  Although some arrangements of pulmonary hypertension aren't curable, treatment can help lessen symptoms and improve the superiority of life. Moreover, pregnancy may have thoughtful threats for women with pulmonary hypertension, so be sure to discuss birth control decisions with the physician.

Gene mutation

Congenital heart disease



Liver disease


Track 10: Respiratory diseases

Respiratory diseases are the common and important reason of illness and death around worldwide. In the UK, approximately 1 in 7 individuals are affected by some category of chronic lung disease. People with respiratory disease have trouble respiration from a limitation in processing air out of lungs which further can cause emphysema and chronic bronchitis. The tissues and organs that make exchange of gas probable in higher organisms, and includes conditions of trachea, bronchi, upper respiratory tract, bronchioles, alveoli, pleura and pleural cavity, and the nerves and muscles of breathing occurs in case of uncontrolled situations. They are characterized by a high inflammatory cell recruitment or destructive cycle of infection. Some of the most common are asthma, chronic obstructive pulmonary disease, pulmonary effusion. As CRDs are not remediable; however, various forms of treatment that help dilate major air passages and improve shortness of breath can support control symptoms and increase the quality of life for people with the diseases.

Acute respiratory distress syndrome

Respiratory failure

Hypersensitivity pneumonitis

Pulmonary fibrosis

Upper Respiratory tract infections



Media Partners/Collaborator

A huge thanks to all our amazing partners. We couldn’t have a conference without you!


A huge thanks to all our amazing partners. We couldn’t have a conference without you!